HONZ(SZ:300086)2026-01-30 10:46Financial Performance Forecast - The estimated net profit for 2025 is projected to be a loss between CNY 168 million and CNY 238 million, compared to a loss of CNY 216.21 million in the same period last year [3]. - The estimated loss after deducting non-recurring gains and losses is projected to be between CNY 153 million and CNY 216 million, compared to a loss of CNY 213.10 million in the same period last year [3]. - The estimated impact of non-recurring gains and losses on net profit is approximately -CNY 18 million, primarily from government subsidies and changes in fair value of investment properties [5]. Market Competition and Costs - The main reason for the expected loss is increased competition in the pharmaceutical market, leading to higher sales and marketing expenses while total operating costs exceed total operating revenue [5]. Communication and Assessment - The company has communicated with the accounting firm regarding the performance forecast, and there are no significant discrepancies in financial data [4]. - The performance forecast is based on preliminary calculations by the finance department and is subject to final assessments by evaluation and auditing institutions [7]. Investment Risks - Investors are advised to make cautious decisions and be aware of investment risks due to potential discrepancies in asset impairment and other results [7].